Comparative Pharmacology
Head-to-head clinical analysis: TRIPHED versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPHED versus XYZAL.
TRIPHED vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating symptoms of allergic reactions. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing edema.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
Adults: Triprolidine 2.5 mg / pseudoephedrine 60 mg orally every 4-6 hours, not to exceed 4 doses in 24 hours.
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in adults with normal renal function; clinically, dosing interval adjustments are recommended in renal impairment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Renal excretion of unchanged drug and metabolites accounting for approximately 60-70% of elimination; biliary/fecal elimination accounts for 20-30%.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine